EN DE
Watch Lana Medical Co. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lana Medical Co. (9587) fair value: what the stock is really worth

As of Oct 29, 2026: fair value (intrinsic value) of Lana Medical Co. stock SAR 1.18, price SAR 1.80, upside -34.4%, quality 27 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SA · ISIN SA15TGFKLPH6

LM Lana Medical Co. logo Thin data Oct 29, 2026

Lana Medical Co.

9587 · SR
Expensive, weak quality

Our calculation puts a fair price 34% below what the stock costs today.

Low debt
Revenue last quarter +32% vs. a year ago.
Expensive Growth (revenue 5y +34.4 %/yr in SAR)
Thin margins · 2.6% net margin (TTM)
Fair value 1.18 SAR · Overvalued (−34.4%)
Quality 27/100
Negative free cash flow
Trails peers (4/12)
Narrow moat 30/100 · thin data
Thin data
Watch Lana Medical Co. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

3.87 SAR 1.57 SAR Fair Value 1.18 SAR Dec 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.

How to read this chart

35‑month range 1.57 SAR – 3.87 SAR · fair‑value band 0.8900 SAR – 1.62 SAR · the 1.80 SAR price screens above the 1.18 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.

Follow Lana Medical Co. in your weekly email

Every Wednesday you see whether Lana Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lana Medical Company provides medical services to healthcare sector in the Kingdom of Saudi Arabia. The company operates through five segments: Medical Waste Management, Sale of Medical Equipment, Sale of Medical Supplies, Construction, and Rental.

Show moreShow less

It offers medical devices, including laser hair removal, C02 fractional laser technology, non-surgical HIFU tightening technique, and skin care.

The company also provides medical equipment maintenance; medical supplies; and health care products, including emergency coverage for construction sites and medical services for industrial facilities and cities, medical coverage for projects and events, equipping and operating primary medical clinics, private ambulance services, home hemodialysis services, and health escort rental services.

In addition, it offers infection control solutions; and medical and industrial, pharmaceutical and pharmaceutical, chemical, and slaughterhouse waste management, as well as carbon ash management, non-hazardous waste, public health pests, food health and safety, and environmental consulting services.

Further, the company is involved in dealing with transfer and disposal of hazardous and organic waste services; construction of residential and non-residential buildings; leasing of containers for transportation of construction debris; production of plastic supplies; and construction waste management and investment services.

Additionally, it engages in the maintenance and cleaning of hospitals, medical centers, and general medical complexes; import and export activities; operation of hazardous medical waste treatment facilities and final disposal of hazardous waste; separating and sorting metal and non-metal waste, and scraps and other articles into secondary raw materials; and retail sale of medical equipment, tools, and supplies.

Lana Medical Company was founded in 2010 and is based in Riyadh, the Kingdom of Saudi Arabia.

Stock analysis

Lana Medical Co. (9587) currently trades at 1.80 SAR, while our model-based Fair Value estimate is 1.18 SAR, 34.4% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 2.18 SAR per share, and 4 of the 14 models we run sit above the 1.80 SAR price.

Bear case: the Asset-Based group reads lowest at 0.3200 SAR, and 10 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.8900 SAR (bear) to 1.62 SAR (bull), the price of 1.80 SAR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Lana Medical Co. reported revenue of 92.3M SAR in FY2025 versus 32.0M SAR in FY2021, a compound +30.4%/yr. Reported net income was 2.7M SAR in FY2025, compounding −20.0%/yr from FY2021.

Key figures

Market cap 97.1M SAR (≈ $25.9M) Micro · P/E ratio 36.0 · P/S ratio 0.90 · EPS (TTM) 0.0500 SAR · Net margin 2.6% · Return on equity 4.3% · Return on assets (EBIT) 7.5% · Operating margin 6.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 36% fair-value upside, at −34%, 9587 screens richer than that median.

Fair Value models

Bear 0.8900 SAR Fair Value 1.18 SAR Bull 1.62 SAR
Price 1.80 SAR · Upside -34.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0415 SAR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV 0.8900 SAR 1.03 SAR 1.16 SAR 74
ROIC Compounder 0.8900 SAR 1.03 SAR 1.16 SAR 72
Residual Income 0.9000 SAR 0.9000 SAR 0.9300 SAR 71
All 14 models by family
Earnings-Based
Graham-Dodd 0.3400 SAR 2.37 SAR 3.32 SAR 63
Lynch FV 1.13 SAR 1.62 SAR 2.10 SAR 61
PEG = 1.0 1.13 SAR 1.62 SAR 2.10 SAR 57
EPV 0.8900 SAR 1.03 SAR 1.16 SAR 74
Multiples
P/E Multiple 0.8200 SAR 1.10 SAR 1.37 SAR 63
P/S Multiple 0.6400 SAR 0.8500 SAR 1.06 SAR 58
P/B Multiple 4.06 SAR 5.42 SAR 6.77 SAR 55
EV/EBIT 1.15 SAR 1.63 SAR 2.11 SAR 65
EV/EBITDA 2.01 SAR 2.78 SAR 3.55 SAR 67
EV/Revenue 0.7400 SAR 1.18 SAR 1.62 SAR 53
Asset-Based
NCAV (Graham) 0.2100 SAR 0.3200 SAR 0.4000 SAR 54
Economic Profit
Residual Income 0.9000 SAR 0.9000 SAR 0.9300 SAR 71
ROIC Compounder 0.8900 SAR 1.03 SAR 1.16 SAR 72
Growth Earnings
Growth-Adj P/E 1.53 SAR 2.18 SAR 2.83 SAR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 31
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 42
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Momentum 12
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 41
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.4%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.0%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−18.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−18.6%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 7%

9587 screens overvalued: fair value 34% below the price. Compare with McKesson Corporation →

Compare Lana Medical Co. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 79 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −34.4% · Bottom 25%
Profitability
Return on equity (12 months) 4.3% · Below median
Return on assets 2.0% · Below median
Net margin (12 months) 2.6% · Above median
Operating margin (12 months) 6.5% · Above median
Growth and dividend
Revenue growth (quarter YoY) 32.4% · Top 25%
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (12 months) 36.0× · Priciest 25%
P/B 1.49× · Priciest 25%
P/S (12 months) 0.90× · Pricier than median
EV/EBITDA 9.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 53
FUTURE (revenue growth)100 · sector 24
PAST (return on equity)17 · sector 27
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 57

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$15.96 HK$59.16 +271% vs 9587
Shanghai Pharmaceuticals Holding 601607 ¥16.54 ¥42.67 +158% vs 9587
Jointown Pharmaceutical Group 600998 ¥5.13 ¥11.56 +125% vs 9587
China National Medicines Corporation 600511 ¥27.80 ¥58.47 +110% vs 9587
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.53 ¥26.64 +36% vs 9587
Henry Schein, Inc HSIC $84.25 $78.17 −7% vs 9587
McKesson Corporation MCK $992.87 $822.74 −17% vs 9587
Galenica AG GALE CHF 87.90 CHF 61.79 −30% vs 9587
Cencora, Inc COR $330.00 $215.20 −35% vs 9587
Cardinal Health, Inc CAH $251.54 $162.84 −35% vs 9587

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lana Medical Co. · Fair Value
1.18 SAR −34%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lana Medical Co. Fair Value". https://www.fairvalue-calculator.com/stock/9587

Frequently asked questions

Is Lana Medical Co. (9587) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of 1.18 SAR versus a price of 1.80 SAR, about −34% upside (overvalued).
What is the fair value of 9587?
Our model-based fair value for Lana Medical Co. is 1.18 SAR (as of Oct 29, 2026), built from audited fundamentals. The current price: 1.80 SAR.
What is the quality score of 9587?
Lana Medical Co. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lana Medical Co. (9587)?
Our model-based price target is the fair value of 1.18 SAR (as of Oct 29, 2026) from 14 valuation models. Cautious scenario 0.8900 SAR, optimistic scenario 1.62 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Lana Medical Co. stock forecast for 2026?
Our models put fair value at 1.18 SAR, about −34% upside versus a price of 1.80 SAR (overvalued). Cautious scenario 0.8900 SAR, optimistic scenario 1.62 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Lana Medical Co. (9587)?
Lana Medical Co. reported trailing-twelve-month revenue of about 108M SAR (latest available figure, as of Oct 29, 2026).
What is the intrinsic value of Lana Medical Co. (9587)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lana Medical Co. it is 1.18 SAR per share (as of Oct 29, 2026), against a price of 1.80 SAR. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Lana Medical Co. stock overvalued or undervalued in 2026?
As of Oct 29, 2026, 9587 trades above its calculated fair value: price 1.80 SAR, fair value 1.18 SAR, a gap of about −34% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9587?
No. The price is what the market pays today (1.80 SAR); the fair value is what the company's own numbers justify (1.18 SAR). For Lana Medical Co. the two are 0.6200 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Lana Medical Co. worth?
The market values Lana Medical Co. at about 97.1M SAR (market capitalisation, as of Oct 29, 2026). Per share that is 1.80 SAR; our models calculate a fair value of 1.18 SAR per share.
What do the bullish and bearish scenarios say about 9587?
Our models span a range for Lana Medical Co.: cautious scenario 0.8900 SAR, base 1.18 SAR, optimistic 1.62 SAR per share (as of Oct 29, 2026, price 1.80 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9587?
Lana Medical Co. trades at a price-to-earnings ratio of 36.0 (as of Oct 29, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.18 SAR is built from several models across several years. Other multiples: P/B 1.5, P/S 0.9, EV/EBITDA 9.1.
How solid is the balance sheet of Lana Medical Co. (9587)?
Balance-sheet figures for Lana Medical Co. (as of Oct 29, 2026): return on equity 4.3%, debt of 0.06 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is 9587 from its 52-week high?
Lana Medical Co. trades at 1.80 SAR, about 47% below its 52-week high of 3.40 SAR and 15% above the low of 1.57 SAR (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 1.18 SAR is for.
Which stocks are comparable to Lana Medical Co.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lana Medical Co. stock attractive at the current price?
The data as of Oct 29, 2026: price 1.80 SAR, calculated fair value 1.18 SAR (−34%), Quality Score 27/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9587 calculated?
We run Lana Medical Co. through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.18 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Lana Medical Co. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lana Medical Co. (9587)?
The closing price on Oct 29, 2026 was 1.80 SAR. Our model-based fair value is 1.18 SAR, about −34% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lana Medical Co. right now?
The price sits above even our optimistic bull case (1.62 SAR). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.8900 SAR to 1.62 SAR) leaves room in how you read the outcome.

Key figures of Lana Medical Co.

How large is the market capitalisation of Lana Medical Co. (9587)?
The market capitalisation of Lana Medical Co. is 97.1M SAR (≈ $25.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lana Medical Co. (9587)?
The price-to-sales ratio of Lana Medical Co. is 0.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lana Medical Co. (9587)?
Earnings per share at Lana Medical Co. are 0.0500 SAR (price ÷ EPS = P/E 36.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lana Medical Co. (9587)?
The net margin of Lana Medical Co. is 2.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lana Medical Co. (9587)?
The return on equity (ROE) of Lana Medical Co. is 4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lana Medical Co. (9587)?
On an EBIT basis the return on assets of Lana Medical Co. is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lana Medical Co. (9587)?
The operating margin of Lana Medical Co. is 6.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lana Medical Co. (9587)?
Revenue at Lana Medical Co. is growing +32.4% versus a year earlier (3y avg +31.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lana Medical Co. (9587)?
Earnings per share at Lana Medical Co. are growing +4.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lana Medical Co. (9587) generate?
The free cash flow of Lana Medical Co. is −10.4M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lana Medical Co. (9587) carry?
The net debt of Lana Medical Co. is 15.7M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lana Medical Co. in the live analysis

One click puts Lana Medical Co. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.